Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ZEO ScientifiX Inc OCEL


Primary Symbol: ZEOX

Healthcare Drug Manufacturers - Major
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Company’s product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood.


OTCQB:ZEOX - Post by User

ZEO ScientifiX Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by indaknownewfieon Jun 16, 2021 1:30pm
142 Views
Post# 33395928

Ramping up

Ramping upUS based results from Houston out. News from India and Pakistan in a couple of weeks. 

https://www.pharmaceutical-technology.com/uncategorised/coronavirus-company-news-summary-organicell-regenerative-medicine-announces-positive-results-from-covid-19-drug-trial-moderna-and-magenta-investments-partner-to-distribute-covid-19-vaccine/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities